Search

Your search keyword '"Michels S"' showing total 458 results
Start Over Author "Michels S" Search Limiters Available in Library Collection
458 results on '"Michels S"'

1. Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study

Author

Doepfner JM, Michels S, Graf N, Becker MD, and Freiberg FJ

Subjects
central serous chorioretinopathy - photodynamic therapy - anti-VEGF - subretinal fluid, Ophthalmology, RE1-994
Abstract

Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland; 3Graf Biostatistics, Winterthur, Switzerland Purpose: The objective of the study was to assess the effect of off-label photodynamic therapy (PDT) in combination with intravitreal off-label ziv-aflibercept or off-label aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy (CSC).Patients and methods: Changes in best corrected visual acuity (BCVA) and subfoveal subretinal fluid (sSRF) and maximum subretinal fluid (mSRF) were retrospectively analyzed in a single-center cohort study of 17 patients (18 eyes) with persistent subretinal fluid for more than 3 months of duration of CSC. Treatment efficacy was measured between injection and PDT at 30±15 days, 90±15 days and 180±30 days after PDT.Results: Significant reduction of sSRF and mSRF was shown after therapy with ziv-aflibercept and aflibercept combined with PDT (p

Published
2018

2. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Author

Michels, S., Massutí, B., Vasyliv, I., Stratmann, J., Frank, J., Adams, A., Felip, E., Grohé, C., Rodriguez-Abreu, D., Bischoff, H., Carcereny i Costa, E., Corral, J., Pereira, E., Fassunke, J., Fischer, R.N., Insa, A., Koleczko, S., Nogova, L., Reck, M., Reutter, T., Riedel, R., Schaufler, D., Scheffler, M., Weisthoff, M., Provencio, M., Merkelbach-Bruse, S., Hellmich, M., Sebastian, M., Büttner, R., Persigehl, T., Rosell, R., and Wolf, J.

Published
2024
Full Text
View/download PDF

7. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Author

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M.A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krüger, S., Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K -O, Thomas, R., Zander, T., Schultheis, A.M., Büttner, R., and Wolf, J.

Published
2018
Full Text
View/download PDF

9. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A., additional, Fischer, R.N., additional, Riedel, R., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

10. 1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)

Author

Wiesweg, M., primary, Hense, J., additional, Darwiche, K., additional, Michels, S., additional, Hautzel, H., additional, Kobe, C., additional, Metzenmacher, M., additional, Herold, T., additional, Zaun, G., additional, Laue, K., additional, Drzezga, A., additional, Schildhaus, H-U., additional, Wolf, J., additional, Herrmann, K., additional, and Schuler, M.H.H., additional

Published
2022
Full Text
View/download PDF

11. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A., additional, Fischer, R., additional, Riedel, R., additional, Weber, J.-P., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

12. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

Author

Scheffler, M., primary, Dugan, M., additional, Saleh, M.M., additional, Koleczko, S., additional, Brägelmann, J., additional, Arolt, C., additional, Nogova, L., additional, Riedel, R., additional, Michels, S., additional, Eisert, A., additional, Fischer, R., additional, Scharpenseel, H., additional, Weber, J.-P., additional, Scheel, A.H., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Lafleur, F., additional, Wild, R., additional, Catanzariti, L., additional, Hillmer, A.M., additional, and Wolf, J., additional

Published
2022
Full Text
View/download PDF

13. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

Author

Kron, A., primary, Scheffler, M., additional, Ihle, M., additional, Michels, S., additional, Süptitz, J., additional, Prang, D., additional, Jakobs, F., additional, Nogova, L., additional, Fischer, R.N., additional, Eisert, A.K., additional, Riedel, R., additional, Kron, F., additional, Hillmer, A., additional, Loges, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, and Wolf, J., additional

Published
2022
Full Text
View/download PDF

14. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

Author

Fischer, R.N., primary, George, J., additional, Scheel, A., additional, Schloesser, H., additional, Brossart, P., additional, Engel-Riedel, W., additional, Griesinger, F., additional, Grohé, C., additional, Kern, J.K., additional, Panse, J., additional, Sebastian, M., additional, Serke, M., additional, Wiewrodt, R., additional, Michels, S., additional, Nogova, L., additional, Riedel, R., additional, Weber, J-P., additional, Büttner, R., additional, Thomas, R., additional, and Wolf, J., additional

Published
2022
Full Text
View/download PDF

15. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A.K., additional, Fischer, R.N., additional, Riedel, R., additional, Weber, J-P., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

16. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

Author

Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R., and Wolf, J.

Published
2022

17. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

Author

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., Scheffler, M., Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., and Scheffler, M.

Published
2022

18. The biological effect of small-scale ROS1 aberrations: An in silico analysis

Author

Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J., Scheffler, M., Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J., and Scheffler, M.

Published
2022

19. Small-scale ROS1 aberrations: Functional impact and therapeutic potential

Author

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., Scheffler, M., Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., and Scheffler, M.

Published
2022

20. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort

Author

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R., Wolf, J., Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R., and Wolf, J.

Published
2022

21. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A., additional, Fischer, R., additional, Riedel, R., additional, Weber, J-P., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

23. Dynamic Editors for Well-Typed Expressions

Author

Zsók, V., Koopman, P., Michels, S., Plasmeijer, R., Zsók, V., Koopman, P., Michels, S., and Plasmeijer, R.

Abstract

TFP 2021, Item does not contain fulltext

Published
2021

25. 1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy

Author

Saalfeld, F.C., Möller, J., Michels, S., Grohe, C., Wiesweg, M., Schubart, C., Alt, J., Griesinger, F., Kauffmann-Guerrero, D., Kulhavy, J., Overbeck, T.R., Pelusi, N., Rohde, G., Wesseler, C., Vathiotis, I., Veluswamy, R., Illini, O.M., Rothschild, S.I., Christopoulos, P., and Wermke, M.

Published
2023
Full Text
View/download PDF

27. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

Author

Riedel, R., primary, Heydt, C., additional, Scheel, A., additional, Tumbrink, H., additional, Brägelmann, J., additional, Fassunke, J., additional, Nogova, L., additional, Michels, S., additional, Scheffler, M., additional, Fischer, R., additional, Koleczko, S., additional, Weber, J., additional, Westphal, T., additional, Abdulla, D., additional, Merkelbach-Bruse, S., additional, Sos, M., additional, Büttner, R., additional, and Wolf, J., additional

Published
2021
Full Text
View/download PDF

28. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data

Author

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R., Wolf, J., Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R., and Wolf, J.

Published
2020

29. Small Cell Lung Cancer - Filling the gap between science and patients

Author

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R., Wolf, J., Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R., and Wolf, J.

Published
2020

30. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup

Author

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R., Wolf, J., Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R., and Wolf, J.

Published
2020

31. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

Author

Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R., Wolf, J., Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R., and Wolf, J.

Published
2020

32. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability

Author

Michels, S, Nogova, L, Deschler-Baier, B, Sebastian, M, Schuler, M, Wermke, M, Felip, E, Rodriguez-Abreu, D, Rosell, R, Abdulla, DSY, Fischer, RN, Koleczko, S, Kron, A, Pinto, A, Riedel, R, Scheffler, M, Suptitz, J, Fassunke, J, Merkelbach-Bruse, S, Hellmich, M, Buttner, R, and Wolf, J

Published
2019

36. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration Chroma and Spectri Phase 3 Randomized Clinical Trials

Author

Holz, Fg, Sadda, Sr, Busbee, B, Chew, Ey, Mitchell, P, Tufail, A, Brittain, C, Ferrara, D, Gray, S, Honigberg, L, Martin, J, Tong, B, Ehrlich, Js, Bressler, Nm, Sola, Ff, Schlottmann, P, Zambrano, A, Zeolite, C, Arnold, J, Gillies, M, Luckie, A, Schneltzer, N, de Zaeytijd, J, Boyd, S, Cruess, A, Kertes, P, Lalonde, L, Maberley, D, Laugesen, C, Bodaghi, B, Cohen, Sy, Francais, C, Souied, E, Tadayoni, R, Altay, L, Eter, N, Feltgen, N, Framme, C, Grisanti, S, Holz, F, Pauleikhoff, D, Seres, A, Vajas, A, Varsanyi, B, Boscia, F, Parravano, Mc, Ricci, F, Viola, F, Rechy, Dl, Morales, V, Dijkman, G, Schlingemann, R, Reategui, G, Raczynska, D, Romanowska-Dixon, B, Teper, S, Kacerik, M, Lipkova, B, Oddelenie, O, Mikova, H, Araiz, J, Arias, L, Mataix, J, Mones, J, Montero, J, Sararols, L, Michels, S, Brand, C, Dhillon, B, Agarwal, A, Alfaro, V, Baker, B, Berger, B, Bhisitkul, R, Blodi, B, Boyer, D, Brooks, Hl, Burgess, S, Busquets, M, Callanan, D, Chan, C, Chang, J, Chen, S, Combs, J, Dhoot, D, Dugel, P, Eichenbaum, D, Feist, R, Ferrone, P, Fine, H, Fortun, J, Fox, Ga, Fu, A, Gentile, R, Ghorayeb, G, Gill, M, Gonzalez, V, Gordon, C, Gupta, S, Hampton, R, Heier, J, Hershberger, V, Higgins, P, Ie, D, Isernhagen, R, Katz, R, Kokame, G, Kwun, R, Lee, P, Lee, S, Mansour, S, Marcus, D, Maturi, R, Michels, M, Moore, J, Nielsen, J, Novalis, G, Ober, M, Olsen, K, Patel, S, Pieramici, D, Raskauskas, P, Rofagha, S, Ruby, A, Schneiderman, T, Schwartz, S, Shah, R, Sheth, V, Singerman, L, Singh, R, Sjaarda, R, Stoller, G, Stoltz, R, Suner, I, Tabassian, A, Tarantola, R, Thach, A, Ufret-Vincenty, R, Wirthlin, R, Witkin, A, Wong, R, Wood, M, Zheutlin, J, Alezzandrini, A, Cartier, Mm, Chauhan, D, Chen, F, Gilhotra, J, Guymer, R, Kwan, A, Schmidt-Erfurth, U, Jacob, J, Postelmans, L, Larsen, M, Garcher, Cc, Bocage, C, Devin, F, Kodjikian, L, Korobelnik, Jf, Said, Sm, Weber, M, Agostini, H, Auffarth, G, Bartz-Schmidt, U, Bell, K, Gamulescu, A, Hattenbach, L, Lohmann, Cp, Wolf, A, Nemeth, J, Vamosi, P, Bandello, F, Eandi, C, Lanzetta, P, Nicolo, M, Staurenghi, G, Virgili, G, Franco, Rg, Estudillo, Jr, Hoyng, C, Fernandez, C, Guzman, M, Lujan, S, Herba, E, Kaluzny, J, Misiuk-Hojlo, M, Nawrocki, J, Carneiro, A, Figueira, J, Silva, R, Vaz-Pereira, S, Abdulaeva, E, Erichev, V, Zolotarev, A, Cernak, A, Figueroa, M, Gallego-Pinazo, R, Garcia-Layana, A, Ulla, Fg, Navarro, R, Ortiz, Jm, Imaz, Rt, Kvanta, A, Hatz, K, Wolf, S, Eldem, B, Kir, N, Mentes, J, Saatci, O, Yilmaz, G, Bailey, C, Banerjee, S, Browning, A, Esposti, S, Gale, R, Ghanchi, F, Jackson, T, Lotery, A, Mahmood, S, Mohamed, Q, Narendran, N, Pearce, I, Williams, M, Abraham, P, Abrams, G, Adrean, S, Antoszyk, A, Baker, C, Breazeale, R, Bridges, Wz, Brown, Dm, Calzada, J, Campochiaro, P, Chaudhry, N, Clark, L, Connolly, B, Csaky, K, Do, D, Dreyer, R, Durant, W, Eaton, A, Feiner, L, Ferreyra, H, Flaxel, C, Foxman, S, Freund, Kb, Gonzales, Cr, Gordon, A, Halperin, L, Ho, A, Holekamp, N, Husain, D, Jain, N, Javid, C, Johnson, M, Kiss, S, Lad, E, Leng, T, Liu, M, London, N, Madow, B, Miller, D, Morse, L, Ohr, M, Oliver, S, Pearlman, J, Ray, Sk, Regillo, C, Rosa, R, Rosenfeld, P, Saperstein, D, Sarraf, D, Shildkrot, Y, Suan, E, Weishaar, P, Wieland, M, Williams, D, Williams, J, Wykoff, Cc, Ophthalmology, ACS - Atherosclerosis & ischemic syndromes, ANS - Cellular & Molecular Mechanisms, and ANS - Systems & Network Neuroscience

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Visual acuity, Population, Visual Acuity, Urology, law.invention, Lesion, Immunoglobulin Fab Fragments, Macular Degeneration, 03 medical and health sciences, 0302 clinical medicine, Atrophy, Double-Blind Method, Randomized controlled trial, law, Settore MED/30, Geographic Atrophy, 80 and over, medicine, Humans, Prospective Studies, Fluorescein Angiography, Prospective cohort study, education, Aged, Original Investigation, Aged, 80 and over, education.field_of_study, business.industry, Middle Aged, Macular degeneration, Complement Factor D, Female, Intravitreal Injections, Treatment Outcome, medicine.disease, Clinical trial, Ophthalmology, 030104 developmental biology, 030221 ophthalmology & optometry, medicine.symptom, business
Abstract

Importance Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials. Objective To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA. Design, Setting, and Participants Two identically designed phase 3 double-masked, randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50 years or older, with bilateral GA and no prior or active choroidal neovascularization in either eye and GA lesions in the study eye measuring 2.54 to 17.78 mm 2 with diffuse or banded fundus autofluorescence patterns. Interventions Participants were randomized 2:1:2:1 to receive 10 mg of intravitreous lampalizumab every 4 weeks, sham procedure every 4 weeks, 10 mg of lampalizumab every 6 weeks, or sham procedure every 6 weeks, through 96 weeks. Main Outcomes and Measures Safety and efficacy assessed as mean change from baseline in GA lesion area at week 48 from centrally read fundus autofluorescence images of the lampalizumab arms vs pooled sham arms, in the intent-to-treat population and by complement factor I–profile genetic biomarker. Results A total of 906 participants (553 women and 353 men; mean [SD] age, 78.1 [8.1] years) were enrolled in Chroma and 975 participants (578 women and 397 men; mean [SD] age, 77.9 [8.1] years) were enrolled in Spectri; 1733 of the 1881 participants (92.1%) completed the studies through 48 weeks. The adjusted mean increases in GA lesion area from baseline at week 48 were 1.93 to 2.09 mm 2 across all groups in both studies. Differences in adjusted mean change in GA lesion area (lampalizumab minus sham) were −0.02 mm 2 (95% CI, −0.21 to 0.16 mm 2 ; P = .80) for lampalizumab every 4 weeks in Chroma, 0.16 mm 2 (95% CI, 0.00-0.31 mm 2 ; P = .048) for lampalizumab every 4 weeks in Spectri, 0.05 mm 2 (95% CI, −0.13 to 0.24 mm 2 ; P = .59) for lampalizumab every 6 weeks in Chroma, and 0.09 mm 2 (95% CI, −0.07 to 0.24 mm 2 ; P = .27) for lampalizumab every 6 weeks in Spectri. No benefit of lampalizumab was observed across prespecified subgroups, including by complement factor I–profile biomarker. Endophthalmitis occurred after 5 of 12 447 injections (0.04%) or in 5 of 1252 treated participants (0.4%) through week 48. Conclusions and Relevance In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment. Results highlight the substantial and consistent enlargement of GA, at a mean of approximately 2 mm 2 per year. Trial Registration ClinicalTrials.gov Identifier:NCT02247479andNCT02247531

Published
2018
Full Text
View/download PDF

37. OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

Author

Fischer, R., primary, George, J., additional, Scheel, A., additional, Schlösser, H., additional, Vehreschild, M., additional, Abdulla, D., additional, Koleczko, S., additional, Michels, S., additional, Nogova, L., additional, Riedel, R., additional, Scheffler, M., additional, Maas, L., additional, Brossart, P., additional, Engel-Riedel, W., additional, Griesinger, F., additional, Grohé, C., additional, Kern, J., additional, Hermes, B., additional, Nachtkamp, K., additional, Panse, J., additional, Sebastian, M., additional, Lehmann, M., additional, Wiewrodt, R., additional, Buettner, R., additional, Thomas, R., additional, and Wolf, J., additional

Published
2019
Full Text
View/download PDF

38. Genomic and clinical characterization of non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3

Author

Scheffler, M., primary, Chanra, T., additional, Kron, A., additional, Koleczko, S., additional, Abdulla, D.S.Y., additional, Ihle, M.A., additional, Holzem, A., additional, Riedel, R., additional, Michels, S., additional, Fischer, R.N., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Nogova, L., additional, and Wolf, J., additional

Published
2019
Full Text
View/download PDF

39. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance

Author

Michels, S., primary, Massuti Sureda, B., additional, Schildhaus, H.-U., additional, Franklin, J., additional, Sebastian, M., additional, Felip, E., additional, Grohe, C., additional, Rodríguez-Abreu, D.F., additional, Bischoff, H., additional, Carcereny Costa, E., additional, Corral Jaime, J., additional, Insa, A., additional, Reck, M., additional, Scheffler, M., additional, Karachaliou, N., additional, Merkelbach-Bruse, S., additional, Nogova, L., additional, Büttner, R., additional, Rosell, R., additional, and Wolf, J., additional

Published
2019
Full Text
View/download PDF

40. FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

Author

Nogova, L., primary, Malchers, F., additional, Hillmer, A., additional, Merkelbach-Bruse, S., additional, Pinto, A., additional, Woempner, C., additional, Riedel, R., additional, Scheffler, M., additional, Michels, S., additional, De Porre, P., additional, Santiago-Walker, A., additional, Fischer, R.N., additional, Abdulla, D.S., additional, Thomas, R., additional, Buettner, R., additional, and Wolf, J., additional

Published
2019
Full Text
View/download PDF

41. Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)

Author

Scheffler, M., primary, Frank, R., additional, Ihle, M.A., additional, Abdulla, D.S., additional, Koleczko, S., additional, Nogova, L., additional, Holzem, A., additional, Chanra, T., additional, Riedel, R., additional, Michels, S., additional, Fischer, R.N., additional, Kron, A., additional, Merkelbach-Bruse, S., additional, Buettner, R., additional, and Wolf, J., additional

Published
2019
Full Text
View/download PDF

42. New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer

Author

Fassunke, J., primary, Heydt, C., additional, Michels, S., additional, Van Veggel, B., additional, Müller, F., additional, Keul, M., additional, Dammert, M.A., additional, Schmitt, A., additional, Smit, E.F., additional, Kast, S., additional, Wolf, J., additional, Buettner, R., additional, Sos, M.L., additional, Rauh, D., additional, and Merkelbach-Bruse, S., additional

Published
2019
Full Text
View/download PDF

44. Metis: An Integrated Reference Architecture for Addressing Uncertainty in Decision-support Systems

Author

Huijbrechts, B., Velikovaa, M., Michels, S., and Scheepens, R.

Subjects
Communication & Information, TS - Technical Sciences, Uncertainty, Probabilistic reasoning, ESI - Embedded Systems Innovation, Actionable intelligence, Trust, Automated situational understanding, Software Science, Safety, Information fusion, Safety and Security, Infostructures, Defence, Safety and Security, Information Society
Abstract

Deliver “actionable” intelligence instead of just raw information – this is what the Metis research project pursues for supporting operational work in domains characterized by constantly evolving situations with a diversity of entities, complex interactions and high-level uncertainty in the information gathered. Operating effectively in such domains requires robust, on-the-fly and context-based information reasoning, which goes beyond human capabilities. In this paper a real-time reference architecture is presented employing and integrating several state-of-the-art computing technologies for automated and consolidated ‘situational understanding’. In particular, outlined are the innovative components (i) for fusing of and reasoning on uncertain information based on probabilistic logic and (ii) for a complementary interactive visualization disclosing the system’s line of reasoning inferred from the domain model and provided evidence. The architecture has been realized as a fully demonstrable proof of concept and its applied value is illustrated in a number of real and fictive cases from the domain of maritime safety and security.

Published
2015

46. FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress)

Author

Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R., Wolf, J., Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R., and Wolf, J.

Published
2018

47. BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer

Author

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R., Wolf, J., Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R., and Wolf, J.

Published
2018

49. Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations

Author

Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M., Wolf, J., Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M., and Wolf, J.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results